Abstract
In 2009, the groundbreaking Iressa Pan-Asia Study (IPASS)1 showed the activity of gefitinib, a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and marked a pivotal shift in the treatment of advanced non–small-cell lung cancer (NSCLC) toward precision medicine. The trial highlighted the importance of identifying actionable genetic alterations in approximately a third of the cases, predominantly adenocarcinomas. This advancement underscores the necessity for detailed molecular analysis of tumors to personalize therapy. In addition, the emergence of different TKIs then allowed a focus on the management of brain metastases, which occur in 20 to 60% of patients with .
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
